Usa Britain state California city Oxford covid-19 testing RNA bill Usa Britain state California city Oxford

Exscientia forms UK-US partnership to screen possible Covid-19 drugs

Reading now: 301
www.pharmaceutical-technology.com

Artificial intelligence (AI) drug discovery company Exscientia has expanded its ongoing anti-viral drugs partnership with the UK’s national synchrotron facility Diamond Light Source and University of Oxford across the Atlantic Ocean to include California-based Scripps Research’s Calibr and focus on Covid-19 research.

The UK-US partners will collaborate to screen most approved and investigational drugs against Covid-19 targets involved in viral replication and entry into human cells.

The prioritised targets include 3CL protease, the NSP12-NSP7-NSP8 RNA polymerase complex and the novel coronavirus’ SPIKE protein, which interacts with the human cell receptor ACE2 to gain entry into human cells.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA